Impact of baseline and interim quantitative PET parameters on outcomes of classical Hodgkin Lymphoma

被引:0
作者
Fernanda Maria Santos
Jose Flavio Gomes Marin
Marcos Santos Lima
Wellington Fernandes Silva-Junior
Lucas Bassolli O. Alves
Frederico R. Moreira
Rodrigo Dolphini Velasques
Marcelo Junqueira Atanazio
Ana Carolina Arrais Maia
Carlos A. Buchpiguel
Valeria Buccheri
Vanderson Rocha
机构
[1] Faculdade de Medicina,Instituto Do Cancer Do Estado de Sao Paulo (ICESP)
[2] Universidade de Sao Paulo (FMUSP),Nuclear Medicine Medical Investigation Laboratory LIM43
[3] Hospital das Clinicas,Division of Hematology and Cell Therapy
[4] FMUSP (HCFMUSP),Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco
[5] HCFMUSP,Immuno
[6] HCFMUSP,Hematology (LIM
[7] Churchill Hospital,31), Department of Internal Medicine, Division of Hematology
[8] NHS BT,Department of Hematology
[9] Oxford University,undefined
来源
Annals of Hematology | 2024年 / 103卷
关键词
Hodgkin lymphoma; Positron emission tomography; Metabolic tumor volume; Total lesion glycolysis;
D O I
暂无
中图分类号
学科分类号
摘要
Currently, analysis of interim PET (iPET) according to the Deauville score (DS) is the most important predictive factor in Hodgkin lymphoma (HL); however, there is room for improvement in its prognostic power. This study aimed to evaluate the prognostic value of quantitative PET analysis (maximum standard uptake value [SUVmax], total metabolic tumor volume [TMTV] and total lesion glicolysis [TLG]) at baseline (PET0) and iPET in a retrospective cohort of newly diagnosed classical HL. For positive iPET (+ iPET), the reduction of quantitative parameters in relation to PET0 (ΔSUVmax, ΔTMTV and ΔTLG) was calculated. Between 2011 and 2017, 234 patients treated with ABVD were analyzed. Median age was 30 years-old, 59% had advanced stage disease, 57% a bulky mass and 25% a + iPET (DS 4–5). At baseline, high TLG was associated with an increased cumulative incidence of failure (CIF) (p = 0.032) while neither SUVmax, TMTV or TLG were associated with overall survival (OS) or progression-free survival (PFS). In multivariate analysis, only iPET was associated with CIF (p < 0.001). Among ΔSUVmax, ΔTMTV and ΔTLG, only a ΔSUVmax ≥ 68.8 was significant for PFS (HR: 0.31, CI95%: 0.11–0.86, p = 0.024). A subset of patients with improved PFS amongst + iPET was identified by the quantitative (ΔSUVmax ≥ 68.8%) analysis. In this real-world Brazilian cohort, with prevalent high-risk patients, quantitative analysis of PET0 did not demonstrate to be prognostic, while a dynamic approach incorporating the ΔSUVmax to + iPET succeeded in refining a subset with better prognosis. These findings warrant validation in larger series and indicate that not all patients with + iPET might need treatment intensification.
引用
收藏
页码:175 / 183
页数:8
相关论文
共 50 条
[31]   An Update on the Role of Interim Restaging FDG-PET in Patients With Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma [J].
Moskowitz, Craig H. ;
Zelenetz, Andrew ;
Schoder, Heiko .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2010, 8 (03) :347-352
[32]   Prognostic parameters on baseline and interim [18F]FDG-PET/computed tomography in diffuse large B-cell lymphoma patients [J].
Czibor, Sandor ;
Carr, Robert ;
Redondo, Francisca ;
Auewarakul, Chirayu U. ;
Cerci, Juliano J. ;
Paez, Diana ;
Fanti, Stefano ;
Gyorke, Tamas .
NUCLEAR MEDICINE COMMUNICATIONS, 2023, 44 (04) :291-301
[33]   Clinical and prognostic role of interim 18F-FDG PET/CT in elderly Hodgkin lymphoma: a dual-center experience [J].
Albano, Domenico ;
Mazzoletti, Angelica ;
Zilioli, Vittorio Ruggero ;
Muzi, Cristina ;
Crucitti, Lara ;
Tucci, Alessandra ;
Pagani, Chiara ;
Re, Alessandro ;
Rossetti, Claudio ;
Giubbini, Raffaele ;
Bertagna, Francesco .
LEUKEMIA & LYMPHOMA, 2020, 61 (13) :3209-3216
[34]   Combined Modality Treatment for PET-Positive Non-Hodgkin Lymphoma: Favorable Outcomes of Combined Modality Treatment for Patients With Non-Hodgkin Lymphoma and Positive Interim or Postchemotherapy FDG-PET [J].
Halasz, Lia M. ;
Jacene, Heather A. ;
Catalano, Paul J. ;
Van den Abbeele, Annick D. ;
LaCasce, Ann ;
Mauch, Peter M. ;
Ng, Andrea K. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 83 (05) :E647-E654
[35]   Interim FDG-PET/CT for therapy monitoring and prognostication in Hodgkin's Lymphoma [J].
Al-Ibraheem, Akram ;
Anwer, Farah ;
Juweid, Malik E. ;
Shagera, Qaid Ahmed ;
Khalaf, Aysar N. ;
Obeidat, Shahed ;
Mansour, Areen ;
Ma'koseh, Mohammad ;
Halahleh, Khalid ;
Jaradat, Imad ;
Almasri, Nidal ;
Mansour, Asem .
SCIENTIFIC REPORTS, 2022, 12 (01)
[36]   Does interim PET increase the value of ABVD in advanced-stage Hodgkin lymphoma? [J].
Gallamini, A. ;
Kostakoglu, L. .
ANNALS OF ONCOLOGY, 2015, 26 (06) :1045-1047
[37]   Interim FDG-PET in Hodgkin lymphoma: a compass for a safe navigation in clinical trials? [J].
Gallamini, Andrea ;
Kostakoglu, Lale .
BLOOD, 2012, 120 (25) :4913-4920
[38]   Interim FDG-PET/CT in Hodgkin lymphoma: what are we actually looking at? [J].
Adams, Hugo J. A. ;
Kwee, Thomas C. .
ACTA ONCOLOGICA, 2018, 57 (08) :1128-1130
[39]   Interim 18F-FDG PET in Hodgkin Lymphoma: Would PET-Adapted Clinical Trials Lead to a Paradigm Shift? [J].
Kostakoglu, Lale ;
Gallamini, Andrea .
JOURNAL OF NUCLEAR MEDICINE, 2013, 54 (07) :1082-1093
[40]   Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma [J].
Mehta-Shah, Neha ;
Ito, Kimiteru ;
Bantilan, Kurt ;
Moskowitz, Alison J. ;
Sauter, Craig ;
Holwitz, Steven M. ;
Schoder, Heiko .
BLOOD ADVANCES, 2019, 3 (02) :187-197